A Cost Comparison Across Drug Development’s Three Hardest Arenas
Vaccines, oncology, and rare disease programs each carry distinct cost structures, attrition profiles, and funding dynamics. Understanding the differences serves […]
Playing to Win: How Competitive Intelligence Shapes Drug Development Strategy
Drug development is expensive, slow, and brutally competitive. A Phase 3 study failure costs hundreds of millions of dollars. A
Most Teams Prepare the Dossier. Few Prepare the Pathway.
When developing novel life science technologies, drugs, biologics, and gene or cell therapies, how often do early-stage teams conduct a
Why Regulatory Strategy Belongs in the Investment Thesis — Not the To-Do List
*A summary of Pathway Capital’s whitepaper on regulatory strategy in early-stage life science investment There is a gap in how